DrugSynthAI is a computational research platform. It is not a medical device.
A platform for computational drug discovery research. It uses gene panels and disease context as query inputs to a multi-agent governed pipeline that proposes candidate therapeutic molecules for downstream wet-lab evaluation by qualified research scientists.
Academic and industry research collaborators conducting drug discovery research. Use of DrugSynthAI output for any purpose other than research is unauthorized.
All candidate molecules, peptides, and antibodies proposed by the platform are computational hypotheses. They are unvalidated and may have any of the following properties: no binding affinity, toxicity, off-target effects, immunogenicity, poor pharmacokinetics, lack of efficacy, novel mechanisms not predicted by the model, or chemical instability. Wet-lab assays and in vivo studies are required before any inference about therapeutic utility.
DrugSynthAI does not accept individual patient inquiries. If you are a patient seeking medical advice, please consult a licensed physician. If you are a physician with a research question for a rare disease pipeline, contact us through our research partnership channel.
Output is provided "as is" without any warranty, express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, accuracy, completeness, or non-infringement. Use is at your own risk.
FxMEDUS LLC (Miami, FL). Affiliated with Boston University Department of Computer Science. Sole inventor and operator: Dr. Julian Yin Vieira Borges, MD.